Viollier to Offer Epigenomics' Colorectal Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Swiss diagnostics lab Viollier has obtained rights to offer Epigenomics' molecular test for colorectal cancer detection as a service to patients in Europe beginning July 1.

Berlin-based Epigenomics said that the test is based on its mSEPT9 biomarker and is the first ever blood-based test for colorectal cancer to be offered in Europe. It said that it expects other diagnostic labs in Europe to offer mSEPT9 testing "in due course."

In addition, Epigenomics said that mSEPT9 testing in the US would initially be offered by Quest Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.